Vonafexor

Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research[1][2].

Product Specifications

CAS Number

[1192171-69-9]

Product Name Alternative

EYP001

UNSPSC

12352005

Hazard Statement

H302-H319-H332-H372-H400

Target

FXR; HBV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/vonafexor.html

Purity

99.32

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

O=C(C1=CC2=C(Cl)C(N3CCN(S(=O)(C4=C(Cl)C=CC=C4Cl)=O)CC3)=CC=C2O1)O

Molecular Formula

C19H15Cl3N2O5S

Molecular Weight

489.76

Precautions

P260-P261-P264-P270-P271-P273-P280-P304+P340-P305+P351+P338-P330-P391-P501

References & Citations

[1]Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66 (1) :S690.|[2]Fiorucci S, et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10.|[3]Erken R, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28 (12) :1690-1698.|[4]Hui RW, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022 Jun;27 (2) :127-140.